Drug Profile
PD 72953
Latest Information Update: 19 Jul 2000
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antihyperlipidaemics; Hexanoic acids
- Mechanism of Action Peroxisome proliferator-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 19 Jul 2000 No-Development-Reported for Hyperlipidaemia in USA (Unknown route)
- 21 Jun 2000 Warner-Lambert has merged with Pfizer
- 20 Oct 1998 New profile